Genmab A (GMAB) Current Taxes (2018 - 2026)
Genmab A's (GMAB) quarterly Current Taxes came in at -$21.0 million in Q1 2026, up 57.14% YoY from -$13.4 million in Q1 2025, and down 148.84% on a QoQ basis from $43.0 million in Q4 2025.
Genmab A (GMAB) Current Taxes (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Current Taxes data on file, last reported at -$21.0 million in Q1 2026.
- Quarterly Current Taxes rose 57.14% year-over-year to -$21.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.0 million (up 57.14% YoY) and the FY2025 annual result came in at $43.0 million, down 82.01% from the prior year.
- Current Taxes declined to -$21.0 million in Q1 2026, from $43.0 million in the prior quarter.
- In the past five years, Current Taxes ranged from a high of $239.0 million in Q4 2024 to a low of -$228.0 million in Q3 2024.
- A 4-year average of -$57.9 million and a median of -$53.0 million in 2024 frame the typical range for Current Taxes.
- Annual changes were most pronounced in 2024 — Current Taxes surged 2887.5% — and 2025, when it sank 82.01%.
- Tracing GMAB's Current Taxes over 4 years: stood at $8.0 million in 2023, then surged by 2887.5% to $239.0 million in 2024, then slumped by 82.01% to $43.0 million in 2025, then slumped by 148.84% to -$21.0 million in 2026.
- The last three Current Taxes figures came in at -$21.0 million (Q1 2026), $43.0 million (Q4 2025), and -$217.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 49.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 76.32 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 59,089.99 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.00 Mn |
| Dec 31, 2025 | 43.00 Mn |
| Sep 30, 2025 | -217.00 Mn |
| Jun 30, 2025 | -136.00 Mn |
| Mar 31, 2025 | -49.00 Mn |
| Dec 31, 2024 | 239.00 Mn |
| Sep 30, 2024 | -228.00 Mn |
| Jun 30, 2024 | -161.00 Mn |
| Mar 31, 2024 | -57.00 Mn |
| Dec 31, 2023 | 8.00 Mn |
| Sep 30, 2020 | 1,226.00 |
| Dec 31, 2019 | -162.00 |
| Sep 30, 2019 | 59.32 Mn |
| Dec 31, 2018 | -51.42 Mn |